Joint briefing paper
The proposed EU directive on the protection of trade secrets currently being studied by the European Parliament threatens freedom of speech for journalists and whistle-blowers, and access to scientific data of public interest.
Category: Campaigns
EU trade secrets directive a threat to health, environment, free speech and worker mobility
Joint statement
The proposed trade secrets directive could obstruct recent EU developments on transparency and endangers freedom of information and expression of European citizens. A multi-sectoral NGO coalition calls for greater protections for consumers, journalists, whistleblowers, researchers and workers. Joint statement attached.
A Civil Society Response to the Big Pharma wish list in TTIP
The analysis of the most worrying proposals of the pharmaceutical industry's wish list for the EU-US trade agreement reveals a real threat to European public health systems and democracy.
Joint position paper produced by Commons Network in cooperation with Medicines in Europe Forum (MiEF), International Society of Drug Bulletins (ISDB), Health Action International Europe (HAI-Europe), Universities Allied for Essential Medicines - Europe (UAEM-Europe), Salud por Derecho Foundation and The Working Group on Health, Medicines & Innovation (GTSMI).
WHO Statement on Public Disclosure of Clinical Trial Results: A welcomed commitment on transparency but one that should capitalise on best practices
The International Society of Drug Bulletins (ISDB), Medicines in Europe Forum (MiEF), Health Action International (HAI) Europe, Nordic Cochrane Centre (NCC) and Public Citizen submitted this joint response to the WHO public consultation on public disclosure of clinical trial results.
EMA’s final policy on access to clinical data: proactive access to some data, but strings attached
On 2 October 2014, the European Medicines Agency (EMA) finally adopted its policy on access to clinical data. From 1 January 2015 onwards, the general public will be able to “view on screen” selected parts of trial reports submitted in support of marketing authorisations, and academic and non-commercial researchers will be allowed to download this data. The policy, unfortunately, also gives pharmaceutical companies the upper hand in deciding the contents of the clinical reports by allowing them to redact data on the grounds of “commercial confidentiality”. The implementation of the policy will need careful monitoring.